Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

PF024 MMP-9, Active, Human, Recombinant

MMP-9, Active, Human, Recombinant MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Matrix Metalloproteinase 9, Gelatinase B, 83 kDa Gelatinase

PF024
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
PF024-5UG Plastic ampoule 5 μg
Description
OverviewRecombinant, human MMP-9 purified from transfected mammalian cells and activated with APMA. Active MMP-9 enzyme is APMA-free.
Catalogue NumberPF024
Brand Family Calbiochem®
SynonymsMatrix Metalloproteinase 9, Gelatinase B, 83 kDa Gelatinase
References
ReferencesParsons, S.L., et al. 1997. Br. J. Surg. 84, 160.
Backstrom, J.R., et al. 1996. J. Neuro. 16, 7910.
Lim, G.P., et al. 1996. J. Neurochem. 67, 251.
Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
Sang, Q.X., et al. 1995. Biochim. Biophys. Acta 1251, 99.
Zempo, N., et al. 1994. J. Vasc. Surg. 20, 217.
Birkedal-Hansen, H. 1993. J. Periodontol. 64, 484.
Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
Jeffrey, J.J. 1991. Semin. Perinatol. 15, 118.
Liotta, L.A., et al. 1991. Cell 64, 327.
Harris, E. 1990. N. Engl. J. Med. 322, 1277.
Product Information
ActivityΔA₄₀₅/hour/µg protein ≥8.0 in standard thiopeptolide hydrolysis assays.
EC number3.4.24.35
FormLiquid
FormulationIn 50 mM HEPES, 10 mM CaCl₂, 20% glycerol, 0.005% BRIJ®-35 Detergent, pH 7.5.
PreservativeNone
Quality LevelMQ200
Applications
Application ReferencesZymography Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259. Kleiner, D.E. and Stetler-Stevenson W.G. 1994. Anal. Biochem. 218, 325. Heussen, C. and Dowdle, E.B. 1980. Anal. Biochem. 102, 196. Substrate cleavage assay Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
Biological Information
Purity≥90% by SDS-PAGE
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial use, aliquot into siliconized vials and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
PF024-5UG 07790788056438

Documentation

MMP-9, Active, Human, Recombinant SDS

Title

Safety Data Sheet (SDS) 

MMP-9, Active, Human, Recombinant Certificates of Analysis

TitleLot Number
PF024

References

Reference overview
Parsons, S.L., et al. 1997. Br. J. Surg. 84, 160.
Backstrom, J.R., et al. 1996. J. Neuro. 16, 7910.
Lim, G.P., et al. 1996. J. Neurochem. 67, 251.
Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
Sang, Q.X., et al. 1995. Biochim. Biophys. Acta 1251, 99.
Zempo, N., et al. 1994. J. Vasc. Surg. 20, 217.
Birkedal-Hansen, H. 1993. J. Periodontol. 64, 484.
Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
Jeffrey, J.J. 1991. Semin. Perinatol. 15, 118.
Liotta, L.A., et al. 1991. Cell 64, 327.
Harris, E. 1990. N. Engl. J. Med. 322, 1277.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision06-July-2010 JSW
SynonymsMatrix Metalloproteinase 9, Gelatinase B, 83 kDa Gelatinase
DescriptionRecombinant, human MMP-9 purified from transfected mammalian cells and activated with APMA. Active MMP-9 enzyme is APMA-free. Supplied as the ~83 kDa active enzyme. The proenzyme form of MMP-9 was purified from transfected mammalian cells and activated using the organomercurial compound, 4-aminophenyl mercuric acetate (APMA). APMA is removed through a desalting column. The substrate specificity for MMP-9 is collagen (types IV, V, VII, and X), elastin, and gelatin (type I). Useful for immunoblotting, substrate cleavage, and zymography. Titration is recommended for optimal results in individual systems. Matrix metalloproteinases are members of a unique family of proteolytic enzymes that have a zinc ion at their active sites and can degrade collagens, elastin and other components of the extracellular matrix (ECM). These enzymes are present in normal healthy individuals and have been shown to have an important role in processes such as wound healing, pregnancy, and bone resorption. However, overexpression and activation of MMPs have been linked with a range of pathological processes and disease states involved in the breakdown and remodeling of the ECM. Such diseases include tumor invasion and metastasis, rheumatoid arthritis, periodontal disease, and vascular processes such as angiogenesis, intimal hyperplasia, atherosclerosis, and aneurysms. Recently, MMPs have been linked to neurodegenerative diseases such as Alzheimer's, and amyotrophic lateral sclerosis (ALS). Natural inhibitors of MMPs, tissue inhibitor of matrix metalloproteinases (TIMPs) exist and synthetic inhibitors have been developed which offer hope of new treatment options for these diseases.

Regulation of MMP activity can occur at the level of gene expression, including transcription and translation, level of activation, or at the level of inhibition by TIMPs. Thus, perturbations at any of these points can theoretically lead to alterations in ECM turnover. Expression is under tight control by pro- and anti-inflammatory cytokines and/or growth factors and, once produced the enzymes are usually secreted as inactive zymograms. Upon activation (removal of the inhibitory propeptide region of the molecules) MMPs are subject to control by locally produced TIMPs. All MMPs can be activated in vitro with organomercurial compounds (e.g. 4-aminophenylmercuric acetate), but the agents responsible for the physiological activation of all MMPs have not been clearly defined. Numerous studies indicate that members of the MMP family have the ability to activate one another. The activation of the MMPs in vivo is likely to be a critical step in terms of their biological behavior, because it is this activation that will tip the balance in favor of ECM degradation. The hallmark of diseases involving MMPs appear to be stoichiometric imbalance between active MMPs and TIMPs, leading to excessive tissue disruption and often degradation. Determination of the mechanisms that control this imbalance may open up some important therapeutic options of specific enzyme inhibitors.
FormLiquid
FormulationIn 50 mM HEPES, 10 mM CaCl₂, 20% glycerol, 0.005% BRIJ®-35 Detergent, pH 7.5.
Concentration Label Please refer to vial label for lot-specific concentration
EC number3.4.24.35
Purity≥90% by SDS-PAGE
ActivityΔA₄₀₅/hour/µg protein ≥8.0 in standard thiopeptolide hydrolysis assays.
PreservativeNone
Storage Avoid freeze/thaw
≤ -70°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial use, aliquot into siliconized vials and freeze (-70°C).
Toxicity Standard Handling
ReferencesParsons, S.L., et al. 1997. Br. J. Surg. 84, 160.
Backstrom, J.R., et al. 1996. J. Neuro. 16, 7910.
Lim, G.P., et al. 1996. J. Neurochem. 67, 251.
Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
Sang, Q.X., et al. 1995. Biochim. Biophys. Acta 1251, 99.
Zempo, N., et al. 1994. J. Vasc. Surg. 20, 217.
Birkedal-Hansen, H. 1993. J. Periodontol. 64, 484.
Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
Jeffrey, J.J. 1991. Semin. Perinatol. 15, 118.
Liotta, L.A., et al. 1991. Cell 64, 327.
Harris, E. 1990. N. Engl. J. Med. 322, 1277.
Application referencesZymography Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259. Kleiner, D.E. and Stetler-Stevenson W.G. 1994. Anal. Biochem. 218, 325. Heussen, C. and Dowdle, E.B. 1980. Anal. Biochem. 102, 196. Substrate cleavage assay Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.